Skip to main content
Kyprolis' survival benefit in multiple myeloma validated in late-stage results

Amgen's late-stage study to evaluate Kyprolis, or carfilzomib, in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed multiple myeloma met its primary endpoint, extending survival by 7.9 months. Participants receiving Kyprolis experienced a decrease of 21% in mortality risk compared with patients treated only with lenalidomide and dexamethasone.

Full Story: